Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.7
4.7
Journals
Biomedicines
Special Issues
Epigenetic Regulation of Solid Tumors
share announcement

Epigenetic Regulation of Solid Tumors

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 1067

Special Issue Editors

Dr. Donghong Zhang

E-Mail Website
Guest Editor
Raybiotech, Atlanta, GA 30092, USA
Interests: tumor biology; epigenetics; DNA/RNA methylation; tumor biomarkers
Dr. Yuning Hou

E-Mail Website
Guest Editor
Cancer Animal Models Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
Interests: epigenetics; cancer biology; gastroenterological disorders; animal disease models
Special Issues, Collections and Topics in MDPI journals
Dr. Xina Xie

E-Mail
Guest Editor
The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China
Interests: tumor treatment; tumor prognosis; LncRNA; MicroRNA; histone modification

Special Issue Information

Dear Colleagues,

Tumors are aggressive diseases with a high mortality rate and a costly treatment process. As the majority of cancer cases are firstly diagnosed at an advanced stage and with metastasis, the current management of cancer faces serious challenges, despite the development of advanced therapeutics. Therefore, employing cutting-edge bio-informatics, sequence technology and molecular biology to develop novel biomarkers for the accurate screening, detection, diagnosis, and prognosis prediction of cancer is essential in order to enhance patients’ survival rate.

Increasing evidence indicates that epigenetic modifications, including DNA/RNA methylation, histone modifications, and non-coding RNAs (ncRNAs), have gained substantial attention in recent years, as it is now well established that these aberrations are significant biomarkers for tumor diagnosis, prognosis, and treatment response. Recent studies have identified various epigenetic cancer biomarkers that have already been commercialized, but further validation studies are required to advance their application to the clinical setting. In this Special Issue, the epigenetic biomarkers with the most promising ability to improve cancer diagnosis and prognosis, and continue to improve human health in the future, are discussed.

For this Special Issue, we invite basic and clinical oncologists to submit their contributions, including reviews, new methods, and original research, related to the role of epigenetics in tumor diagnosis and prognosis. We welcome the submission of relevant papers addressing various novel aspects of epigenetics.

Dr. Donghong Zhang
Dr. Yuning Hou
Dr. Xina Xie
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • epigenomics
  • epigenetics
  • tumor diagnosis and prognosis
  • MicroRNA, PI-RNA, LncRNA
  • DNA/RNA methylation
  • histone modifications

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 2618 KiB  
Review
Long Intergenic Non-Coding RNAs of Human Chromosome 18: Focus on Cancers
by Pavel V. Ershov, Evgeniy O. Yablokov, Yuri V. Mezentsev and Alexis S. Ivanov
Biomedicines 2024, 12(3), 544; https://doi.org/10.3390/biomedicines12030544 - 28 Feb 2024
Viewed by 837
Abstract
Malignant neoplasms are characterized by high molecular heterogeneity due to multilevel deregulation of gene expression and cellular functions. It is known that non-coding RNAs, including long intergenic non-coding RNAs (lincRNAs), can play significant roles in cancer biology. The current review focuses on a [...] Read more.
Malignant neoplasms are characterized by high molecular heterogeneity due to multilevel deregulation of gene expression and cellular functions. It is known that non-coding RNAs, including long intergenic non-coding RNAs (lincRNAs), can play significant roles in cancer biology. The current review focuses on a systematical analysis of genomic, transcriptomic, epigenomic, interactomic, and literature data on 65 lincRNAs of human chromosome 18 in the context of pan-cancer studies. The entire group of lincRNAs can be conditionally divided into 4 subgroups depending on experimental evidence on direct or indirect involvement in cancers and the biological associations with cancers, which we found during the data-mining process: the most studied (5 lincRNAs), moderately or poorly studied (11 lincRNAs), and understudied (31 lincRNAs). For the remaining 18 lincRNAs, data for analysis were fragmentary or missing. Among the key findings were the following: Of the lincRNAs of human chromosome 18, 40% have tissue-specific expression patterns, 22% of lincRNAs are known to have gene fusions, 40% of lincRNAs are prone to gene amplifications and/or deletions in cancers at a frequency greater than 3%, and 23% of lincRNAs are differentially expressed across cancer types, whereas 7% have subtype-specific expression patterns. LincRNAs’ interactomes consist of ‘master’ microRNAs and 47 proteins (including cancer-associated proteins and microRNAs) that can interact with 3 or more lincRNAs. Functional enrichment analysis of a set of highly co-expressed genes retrieved for 17 lincRNAs in different cancer types indicated the potential associations of these lincRNAs with cellular signaling pathways. Six lincRNAs encoded small open-reading frame (smORF) proteins with emerging roles in cancers, and microRNAs as well as proteins with known functions in molecular carcinogenesis can bind to coding regions of smORFs. We identified seven transcriptomic signatures with potential prognostic value, consisting of two to seven different lincRNAs only. Taken together, the literature, biomedical, and molecular biology data analyzed indicated that only five of all lincRNAs of human chromosome 18 are cancer-associated, while eleven other lincRNAs have the tendency to be associated with cancers. Full article
(This article belongs to the Special Issue Epigenetic Regulation of Solid Tumors)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop